药物涂层的气球超越了静脉静脉复原
Rahul Gupta1, Chandrashekar Bohra2, Krishna Santosh Vemuri3
1Department of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Reviews in cardiovascular medicine
|March 6, 2026
概括
药物涂层气球 (DCB) 在干预心脏病学中提供了一个有前途的无支架替代方案. 有证据支持它们用于各种冠状动脉病变,可能降低与支架相关的风险.
科学领域:
- 干预心脏病学 干预心脏病学
- 心血管器械 心血管器械
背景情况:
- 药物涂层气球 (DCB) 越来越多地因其在干预心脏病学中的治疗潜力而得到认可.
- 来自试验和元分析的现有证据支持DCB作为冠状动脉病变的无支架替代品.
- DCB的目的是减轻像支架血栓和支架静止 (ISR) 这样的风险,并为高出血风险 (HBR) 患者提供更短的双重抗血小板治疗.
研究的目的:
- 提供药物涂层气球 (DCB) 治疗的全面审查.
- 探索DCB的不断变化的作用和扩展的迹象,超越静脉静脉复缩 (ISR).
主要方法:
- 随机试验,观察性研究和元分析的审查.
- 对支持DCB疗效的临床证据的分析.
- 评估DCB在各种冠状动脉损伤类型中的应用.
主要成果:
- DCBs在广泛的冠状动脉病变中表现出有效性.
- DCBs为传统的支架策略提供了一个可行的替代方案.
- 新出现的证据支持DCB在新发病变,分叉病,HBR患者和急性冠状动脉综合征中的使用.
结论:
- 药物涂层气球 (DCB) 是干预心脏病学的重大进展.
- DCBs提供了一个有价值的无支架选择,具有不断扩大的临床应用.
- 预计DCB疗法将在ISR之外进行进一步的研究和临床采用.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
465
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
465
Coronary Artery Disease V: Interprofessional Care
354
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
558
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
558
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Atherosclerosis III: Management
538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K


